Dentist Role in Increasing Quality of Life in Mucositis Patient with Acute Lymphoblastic Leukemia

Authors

  • Theodora Adhisty Dwiarie Residen Ilmu Penyakit Mulut, Fakultas Kedokteran Gigi, Universitas Padjadjaran, Bandung, Indonesia
  • Nanan Nur’aeny Department of Oral Medicine, Universitas Padjadjaran, Bandung, Indonesia
  • Nelly Nainggolan Oral Medicine Residency Program, Universitas Padjadjaran, Bandung, Indonesia

DOI:

https://doi.org/10.30649/denta.v16i1.2

Keywords:

Acute Lymphoblastic Leukemia, Chemotherapy, Mucositis, Quality of Life

Abstract

Background: Mucositis, a painful condition common in patients undergoing chemotherapy, can decrease the patient's quality of life. Treatment of mucositis by dentists supports the improvement of general health conditions and the patient's quality of life. This case report aims to discuss a case of a patient with mucositis after undergoing chemotherapy treatment for acute lymphoblastic leukemia. Case: 21 years old female diagnosed with acute lymphoblastic leukemia, referred to the oral medicine department from internal medicine, complained of pain in oral mucosa and lockjaw in the last three days after chemotherapy treatment with methotrexate. Internal medicine prescribes ceftriaxone intravenous (IV), dexamethasone IV, chlorhexidine gargle, and nystatin. Intraoral examination showed erosive lesions in the tongue, labial, and buccal mucosa and was diagnosed as oral mucositis grade 3 according to the World Health Organization scale. Her quality-of-life score is 46 according to The Functional Assessment of Cancer Therapy-General (FACT-G) and 58 according to Oropharyngeal Mucositis Quality of Life (OMQoL). Case management: She was treated with magic mouthwash containing diphenhydramine HCL, sucralfate, and aluminum hydroxide-magnesium hydroxide. Chlorhexidine and nystatin were advised to stop. The patient was instructed to keep her oral hygiene by gargling with sodium chloride and povidone-iodine after eating. Five days after the therapy, her condition improved (grade 1), and there was an increase in the FACT-G and OMQoL scores to 54 and 93. Conclusion: Mucositis can cause pain in the patient. A dentist can help diagnose and provide appropriate treatment to reduce the patient's complaints and improve the patient's quality of life.

Downloads

Download data is not yet available.

References

Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J 2017;7(6):e577.

Paul S, Kantarjian H, Jabbour EJ. Adult Acute Lymphoblastic Leukemia. Mayo Clin Proc 2016;91(11):1645–66.

Pavithran S, Sreeleksmi M V., Sreelekshmi R. Oral-health related quality of life of patients on chemotheray. Biomed Pharmacol J 2020;13(1):107–18.

Chaveli-López B, Bagán-Sebastián J V. Treatment of oral mucositis due to chemotherapy. J Clin Exp Dent 2016;8(2):e201–9.

Kirk LM, Brown SD, Luu Y, Ogle A, Huffman J, Lewis PO. Beyond-use dating of lidocaine alone and in two “magic mouthwash” preparations. Am J Heal Pharm 2017;74(9):e202–10.

Pulito C, Cristaudo A, Porta C La, Zapperi S, Blandino G, Morrone A, et al. Oral mucositis: The hidden side of cancer therapy. J Exp Clin Cancer Res 2020;39(1):1–15.

Kwon Y. Mechanism-based management for mucositis: Option for treating side effects without compromising the efficacy of cancer therapy. Onco Targets Ther 2016;9:2007–16.

Cidon EU. Chemotherapy induced oral mucositis: Prevention is possible. Chinese Clin Oncol 2018;7(1).

Poulopoulos A, Papadopoulos P, Andreadis D. Chemotherapy: oral side effects and dental interventions. A review of the literature. Stomatol Dis Sci 2017;1(2):35–49.

Curra M, Soares Junior LAV, Martins MD, Santos PS da S. Chemotherapy protocols and incidence of oral mucositis. An integrative review. Einstein (Sao Paulo) 2018;16(1):eRW4007.

Al-rudayni AHM, Gopinath D, Maharajan MK, Menon RK. Impact of oral mucositis on quality of life in patients undergoing oncological treatment : a systematic review. 2020;9(4):3126–34.

Hurrell L, Burgoyne L, Logan R, Revesz T, Gue S. The Management of Pediatric Oncology Inpatients with Oral Mucositis. J Pediatr Hematol Oncol 2019;41(8):E510–6.

Ahmad P, Akhtar U, Chaudhry A, Rashid U, Saif S, Asif JA. Treatment and prevention of oral mucositis: A literature review. Eur J Gen Dent 2019;8(2):23–8.

Damascena LCL, de Lucena NNN, Ribeiro ILA, Pereira TL, Lima-Filho LMA, Valença AMG. Severe oral mucositis in pediatric cancer patients: Survival analysis and predictive factors. Int J Environ Res Public Health 2020;17(4).

European Oral Care in Cancer Group Oral Care Guidance and Support First Edition.

Lee YH, Hong J, Kim I, Choi Y, Park HK. Prospective evaluation of clinical symptoms of chemotherapy-induced oral mucositis in adult patients with acute leukemia: A preliminary study. Clin Exp Dent Res 2020;6(1):90–9.

Scheibler E, da Silva RM, Leite CE, Campos MM, Figueiredo MA, Salum FG, et al. Stability and efficacy of combined nystatin and chlorhexidine against suspensions and biofilms of Candida albicans. Arch Oral Biol 2018;89(February):70–6.

Haydari M, Bardakci AG, Koldsland OC, Aass AM, Sandvik L, Preus HR. Comparing the effect of 0.06% -, 0.12% and 0.2% Chlorhexidine on plaque, bleeding and side effects in an experimental gingivitis model: A parallel group, double masked randomized clinical trial. BMC Oral Health 2017;17(1):1–8.

James P, Worthington H V., Parnell C, Harding M, Lamont T, Cheung A, et al. Chlorhexidine mouthrinse as an adjunctive treatment for gingival health. Cochrane Database Syst Rev 2017;2017(3).

Brown TJ, Gupta A. Management of cancer therapy-associated oral mucositis. J Oncol Pract 2020;16(3):103–9.

Kusiak A, Alicjajereczek-Fossa B, Cichońska D, Alterio D. Oncological-therapy related oral mucositis as an interdisciplinary problem—literature review. Int J Environ Res Public Health 2020;17(7).

Gutiérrez-Vargas R, Díaz-García ML, Villasís-Keever MÁ, Portilla-Robertson J, Zapata-Tárres M. Instruments to measure the quality of life in patients with oral mucositis undergoing oncological treatment: a systematic review of the literature. Boletín Médico Del Hosp Infant México (English Ed 2016;73(6):457–66.

Berger K, Schopohl D, Bollig A, Strobach D, Rieger C, Rublee D, et al. Burden of Oral Mucositis: A Systematic Review and Implications for Future Research. Oncol Res Treat 2018;41(6):399–405.

Al Barmawi M, Al Hadid L, Alqudah H, Al Hadid W, Shamoun S. Measuring the Quality of Life among Head-and/or-Neck Cancer Patients with Oral Mucositis Using the Functional Assessment of Cancer Therapy-General in Jordan. Asia-Pacific J Oncol Nurs 2018;5(3):320–6.

Nunez-Aguilar J, Oliveros-Lopez LG, Fernandez-Olavarria A, Torres-Lagares D, Serrera-Figallo MA, Gutierrez-Corrales A, et al. Influence of dental treatment in place on quality of life in oral cancer patients undergoing chemoradiotherapy. Med Oral Patol Oral Cir Bucal 2018;23(4):e498–505.

Jung Y-S, Park E-Y, Sohn H-O. Oral Health Status and Oral Health-related Quality of Life According to Presence or Absence of Mucositis in Head and Neck Cancer Patients. J Cancer Prev 2019;24(1):43–7.

Zimmermann C, Meurer MI, Grando LJ, Gonzaga Del Moral JÂ, Da Silva Rath IB, Schaefer Tavares S. Dental Treatment in Patients with Leukemia. J Oncol 2015;2015:1–14.

Kochhar AS, Bhasin R, Kochhar GK, Dadlani H. Provision of continuous dental care for oral oncology patients during & after COVID-19 pandemic. Oral Oncol 2020;106(January).

Downloads

Published

2022-02-28

How to Cite

Theodora Adhisty Dwiarie, Nanan Nur’aeny, & Nelly Nainggolan. (2022). Dentist Role in Increasing Quality of Life in Mucositis Patient with Acute Lymphoblastic Leukemia. DENTA JURNAL KEDOKTERAN GIGI, 16(1), 6–12. https://doi.org/10.30649/denta.v16i1.2

Issue

Vol. 16 No. 1 (2022): Februari

Section

Articles

License

Copyright (c) 2022 DENTA

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Dengan menggunakan Hak Lisensi (sebagaimana didefinisikan di bawah), Anda menerima dan setuju untuk terikat oleh syarat dan ketentuan Lisensi Publik Internasional Creative Commons Atribusi-BerbagiSerupa 4.0 ini ("Lisensi Publik"). Sejauh Lisensi Publik ini dapat diartikan sebagai suatu kontrak, Anda diberikan Hak Lisensi dengan mempertimbangkan penerimaan Anda terhadap syarat dan ketentuan ini, dan Pemberi Lisensi memberikan Anda hak tersebut dengan mempertimbangkan manfaat yang diterima Pemberi Lisensi dari penyediaan Materi Berlisensi berdasarkan syarat dan ketentuan ini.

Bagian 1 – Definisi.

  1. Materi Adaptasi  berarti materi yang tunduk pada Hak Cipta dan Hak Serupa yang berasal dari atau berdasarkan Materi Berlisensi dan di mana Materi Berlisensi tersebut diterjemahkan, diubah, disusun, ditransformasi, atau dimodifikasi dengan cara lain yang memerlukan izin berdasarkan Hak Cipta dan Hak Serupa yang dimiliki oleh Pemberi Lisensi. Untuk tujuan Lisensi Publik ini, jika Materi Berlisensi berupa karya musik, pertunjukan, atau rekaman suara, Materi Adaptasi selalu diproduksi di mana Materi Berlisensi tersebut disinkronkan dalam hubungan waktu dengan gambar bergerak.
  2. Lisensi Adaptor  berarti lisensi yang Anda terapkan pada Hak Cipta dan Hak Serupa dalam kontribusi Anda pada Materi Adaptasi sesuai dengan syarat dan ketentuan Lisensi Publik ini.
  3. Lisensi Kompatibel BY-SA  berarti lisensi yang tercantum di  creativecommons.org/compatiblelicenses , yang disetujui oleh Creative Commons sebagai padanan hakiki dari Lisensi Publik ini.
  4. Hak Cipta dan Hak Serupa  berarti hak cipta dan/atau hak serupa yang berkaitan erat dengan hak cipta, termasuk, namun tidak terbatas pada, hak pertunjukan, hak siaran, hak rekaman suara, dan Hak Basis Data Sui Generis, tanpa memperhatikan bagaimana hak tersebut diberi label atau dikategorikan. Untuk tujuan Lisensi Publik ini, hak-hak yang disebutkan dalam Pasal  2(b)(1)-(2)  bukan merupakan Hak Cipta dan Hak Serupa.
  5. Langkah-Langkah Teknologi yang Efektif  berarti langkah-langkah yang, jika tidak ada kewenangan yang tepat, tidak dapat dielakkan berdasarkan hukum yang memenuhi kewajiban berdasarkan Pasal 11 Perjanjian Hak Cipta WIPO yang diadopsi pada tanggal 20 Desember 1996, dan/atau perjanjian internasional serupa.
  6. Pengecualian dan Batasan  berarti penggunaan wajar, perlakuan wajar, dan/atau pengecualian atau batasan lain terhadap Hak Cipta dan Hak Serupa yang berlaku untuk penggunaan Anda atas Materi Berlisensi.
  7. Elemen Lisensi  berarti atribut lisensi yang tercantum dalam nama Lisensi Publik Creative Commons. Elemen Lisensi dari Lisensi Publik ini adalah Atribusi dan Berbagi Serupa.
  8. Materi Berlisensi  berarti karya seni atau sastra, basis data, atau materi lain yang kepadanya Pemberi Lisensi menerapkan Lisensi Publik ini.
  9. Hak Berlisensi  berarti hak yang diberikan kepada Anda sesuai dengan syarat dan ketentuan Lisensi Publik ini, yang terbatas pada semua Hak Cipta dan Hak Serupa yang berlaku untuk penggunaan Anda atas Materi Berlisensi dan yang Pemberi Lisensi berwenang untuk melisensikannya.
  10. Pemberi lisensi  berarti individu atau badan yang memberikan hak berdasarkan Lisensi Publik ini.
  11. Berbagi  berarti menyediakan materi kepada publik melalui cara atau proses apa pun yang memerlukan izin berdasarkan Hak Lisensi, seperti reproduksi, tampilan publik, pertunjukan publik, distribusi, penyebaran, komunikasi, atau impor, dan menyediakan materi kepada publik termasuk dengan cara yang memungkinkan anggota publik mengakses materi tersebut dari suatu tempat dan pada waktu yang mereka pilih sendiri.
  12. Hak Basis Data Sui Generis  berarti hak-hak selain hak cipta yang timbul dari Direktif 96/9/EC Parlemen Eropa dan Dewan tanggal 11 Maret 1996 tentang perlindungan hukum basis data, sebagaimana telah diubah dan/atau digantikan, serta hak-hak lain yang pada hakikatnya setara di mana pun di dunia.
  13. Anda  berarti individu atau entitas yang menjalankan Hak Lisensi berdasarkan Lisensi Publik ini.  "Anda"  memiliki arti yang sesuai.

Bagian 2 – Ruang Lingkup.

  1. Pemberian lisensi .
    1. Tunduk pada syarat dan ketentuan Lisensi Publik ini, Pemberi Lisensi dengan ini memberikan Anda lisensi yang berlaku di seluruh dunia, bebas royalti, tidak dapat disublisensikan, tidak eksklusif, dan tidak dapat dibatalkan untuk melaksanakan Hak Lisensi dalam Materi Berlisensi untuk:
      1. memperbanyak dan Membagikan Materi Berlisensi, secara keseluruhan atau sebagian; dan
      2. memproduksi, memperbanyak, dan Berbagi Materi yang Diadaptasi.
    2. Exceptions and Limitations. For the avoidance of doubt, where Exceptions and Limitations apply to Your use, this Public License does not apply, and You do not need to comply with its terms and conditions.
    3. Term. The term of this Public License is specified in Section 6(a).
    4. Media and formats; technical modifications allowed. The Licensor authorizes You to exercise the Licensed Rights in all media and formats whether now known or hereafter created, and to make technical modifications necessary to do so. The Licensor waives and/or agrees not to assert any right or authority to forbid You from making technical modifications necessary to exercise the Licensed Rights, including technical modifications necessary to circumvent Effective Technological Measures. For purposes of this Public License, simply making modifications authorized by this Section 2(a)(4) never produces Adapted Material.
    5. Downstream recipients.
      1. Offer from the Licensor – Licensed Material. Every recipient of the Licensed Material automatically receives an offer from the Licensor to exercise the Licensed Rights under the terms and conditions of this Public License.
      2. Additional offer from the Licensor – Adapted Material. Every recipient of Adapted Material from You automatically receives an offer from the Licensor to exercise the Licensed Rights in the Adapted Material under the conditions of the Adapter’s License You apply.
      3. No downstream restrictions. You may not offer or impose any additional or different terms or conditions on, or apply any Effective Technological Measures to, the Licensed Material if doing so restricts exercise of the Licensed Rights by any recipient of the Licensed Material.
    6. No endorsement. Nothing in this Public License constitutes or may be construed as permission to assert or imply that You are, or that Your use of the Licensed Material is, connected with, or sponsored, endorsed, or granted official status by, the Licensor or others designated to receive attribution as provided in Section 3(a)(1)(A)(i).

  2. Other rights.

    1. Moral rights, such as the right of integrity, are not licensed under this Public License, nor are publicity, privacy, and/or other similar personality rights; however, to the extent possible, the Licensor waives and/or agrees not to assert any such rights held by the Licensor to the limited extent necessary to allow You to exercise the Licensed Rights, but not otherwise.
    2. Patent and trademark rights are not licensed under this Public License.
    3. To the extent possible, the Licensor waives any right to collect royalties from You for the exercise of the Licensed Rights, whether directly or through a collecting society under any voluntary or waivable statutory or compulsory licensing scheme. In all other cases the Licensor expressly reserves any right to collect such royalties.

Section 3 – License Conditions.

Your exercise of the Licensed Rights is expressly made subject to the following conditions.

  1. Attribution.

    1. If You Share the Licensed Material (including in modified form), You must:

      1. retain the following if it is supplied by the Licensor with the Licensed Material:
        1. identification of the creator(s) of the Licensed Material and any others designated to receive attribution, in any reasonable manner requested by the Licensor (including by pseudonym if designated);
        2. a copyright notice;
        3. a notice that refers to this Public License;
        4. a notice that refers to the disclaimer of warranties;
        5. a URI or hyperlink to the Licensed Material to the extent reasonably practicable;
      2. indicate if You modified the Licensed Material and retain an indication of any previous modifications; and
      3. indicate the Licensed Material is licensed under this Public License, and include the text of, or the URI or hyperlink to, this Public License.
    2. You may satisfy the conditions in Section 3(a)(1) in any reasonable manner based on the medium, means, and context in which You Share the Licensed Material. For example, it may be reasonable to satisfy the conditions by providing a URI or hyperlink to a resource that includes the required information.
    3. If requested by the Licensor, You must remove any of the information required by Section 3(a)(1)(A) to the extent reasonably practicable.
  2. ShareAlike.

    In addition to the conditions in Section 3(a), if You Share Adapted Material You produce, the following conditions also apply.

    1. The Adapter’s License You apply must be a Creative Commons license with the same License Elements, this version or later, or a BY-SA Compatible License.
    2. You must include the text of, or the URI or hyperlink to, the Adapter's License You apply. You may satisfy this condition in any reasonable manner based on the medium, means, and context in which You Share Adapted Material.
    3. You may not offer or impose any additional or different terms or conditions on, or apply any Effective Technological Measures to, Adapted Material that restrict exercise of the rights granted under the Adapter's License You apply.

Section 4 – Sui Generis Database Rights.

Where the Licensed Rights include Sui Generis Database Rights that apply to Your use of the Licensed Material:

  1. for the avoidance of doubt, Section 2(a)(1) grants You the right to extract, reuse, reproduce, and Share all or a substantial portion of the contents of the database;
  2. if You include all or a substantial portion of the database contents in a database in which You have Sui Generis Database Rights, then the database in which You have Sui Generis Database Rights (but not its individual contents) is Adapted Material, including for purposes of Section 3(b); and
  3. You must comply with the conditions in Section 3(a) if You Share all or a substantial portion of the contents of the database.

For the avoidance of doubt, this Section 4 supplements and does not replace Your obligations under this Public License where the Licensed Rights include other Copyright and Similar Rights.

Section 5 – Disclaimer of Warranties and Limitation of Liability.

  1. Unless otherwise separately undertaken by the Licensor, to the extent possible, the Licensor offers the Licensed Material as-is and as-available, and makes no representations or warranties of any kind concerning the Licensed Material, whether express, implied, statutory, or other. This includes, without limitation, warranties of title, merchantability, fitness for a particular purpose, non-infringement, absence of latent or other defects, accuracy, or the presence or absence of errors, whether or not known or discoverable. Where disclaimers of warranties are not allowed in full or in part, this disclaimer may not apply to You.
  2. To the extent possible, in no event will the Licensor be liable to You on any legal theory (including, without limitation, negligence) or otherwise for any direct, special, indirect, incidental, consequential, punitive, exemplary, or other losses, costs, expenses, or damages arising out of this Public License or use of the Licensed Material, even if the Licensor has been advised of the possibility of such losses, costs, expenses, or damages. Where a limitation of liability is not allowed in full or in part, this limitation may not apply to You.
  1. The disclaimer of warranties and limitation of liability provided above shall be interpreted in a manner that, to the extent possible, most closely approximates an absolute disclaimer and waiver of all liability.

Section 6 – Term and Termination.

  1. This Public License applies for the term of the Copyright and Similar Rights licensed here. However, if You fail to comply with this Public License, then Your rights under this Public License terminate automatically.

  2. Where Your right to use the Licensed Material has terminated under Section 6(a), it reinstates:

    1. automatically as of the date the violation is cured, provided it is cured within 30 days of Your discovery of the violation; or
    2. upon express reinstatement by the Licensor.
    For the avoidance of doubt, this Section 6(b) does not affect any right the Licensor may have to seek remedies for Your violations of this Public License.
  3. For the avoidance of doubt, the Licensor may also offer the Licensed Material under separate terms or conditions or stop distributing the Licensed Material at any time; however, doing so will not terminate this Public License.
  4. Sections 1, 5, 6, 7, and 8 survive termination of this Public License.

Bagian 7 – Syarat dan Ketentuan Lainnya.

  1. Pemberi Lisensi tidak akan terikat oleh ketentuan atau persyaratan tambahan atau berbeda yang dikomunikasikan oleh Anda kecuali disetujui secara tegas.
  2. Segala pengaturan, kesepahaman, atau perjanjian mengenai Materi Berlisensi yang tidak dinyatakan di sini terpisah dari dan independen dari syarat dan ketentuan Lisensi Publik ini.

Bagian 8 – Interpretasi.

  1. Untuk menghindari keraguan, Lisensi Publik ini tidak, dan tidak akan ditafsirkan untuk, mengurangi, membatasi, mengekang, atau memaksakan ketentuan pada penggunaan Materi Berlisensi yang secara sah dapat dilakukan tanpa izin berdasarkan Lisensi Publik ini.
  2. Sedapat mungkin, jika ada ketentuan dalam Lisensi Publik ini yang dianggap tidak dapat diberlakukan, ketentuan tersebut akan secara otomatis direformasi hingga batas minimum yang diperlukan agar dapat diberlakukan. Jika ketentuan tersebut tidak dapat direformasi, ketentuan tersebut akan dihapus dari Lisensi Publik ini tanpa memengaruhi keberlakuan syarat dan ketentuan lainnya.
  3. Tidak ada syarat atau ketentuan Lisensi Publik ini yang akan diabaikan dan tidak ada kegagalan untuk mematuhi yang disetujui kecuali disetujui secara tegas oleh Pemberi Lisensi.
  4. Tidak ada satu pun dalam Lisensi Publik ini yang merupakan atau boleh ditafsirkan sebagai pembatasan atau pengesampingan hak istimewa dan kekebalan apa pun yang berlaku bagi Pemberi Lisensi atau Anda, termasuk dari proses hukum di yurisdiksi atau otoritas mana pun.

Most read articles by the same author(s)